| ||
Covidien expects better 2013 pharmaceutical sales Businessweek Covidien now expects revenue for its Mallinckrodt pharmaceutical business to grow between 3 and 6 percent in 2013, up from a previous estimate of 1 to 4 percent. It said the change reflects good performance from the business and marketing approval for ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment